cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28846574
title: Supplementary Material for: Real World Postural Transitions as Biomarkers of Functional Impairment in Duchenne Muscular Dystrophy

description: Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder that impairs daily functioning and results in premature death. Current clinical assessments are widely used for characterizing functional impairment but have limitations due to their subjective and effort-based nature and because they only capture a snapshot of symptoms at a single point in time. Digital health technologies, such as wearable devices, allow continuous collection of movement and physiological data during daily life and could provide objective measures of the impact of DMD symptoms on daily functioning. For example, measurement of the 95th centile of stride velocity has recently gained endorsement by European regulators as an endpoint for evaluating functional changes in DMD, but the use of wearables for this purpose is just beginning. In this study, we present preliminary investigations of candidate digital biomarkers of functional impairment using real-world data, and further explore the relationships between these parameters and established clinical assessments. We found nine candidate biomarkers for detecting DMD-related functional impairment, all exhibiting large to very large effect sizes in our sample of 14 boys with DMD and matched controls (9 DMD, 5 control, age 4-12 years). Each candidate biomarker was moderately or strongly associated with clinical measures of function in DMD. Six of the biomarkers are novel and/or understudied in DMD including objective measures of gait acceleration and variability; postural control immediately before and after a postural transition; and the smoothness of postural transitions. Notably, postural transition measures were more sensitive to DMD-related impairment than gait, activity, and cardiac measures. These results suggest that the quality of postural transitions could serve as a sensitive and objective measure of functional impairment in DMD and point toward the need for further exploration of these measures in DMD.
DOI: 10.6084/m9.figshare.28846574.v1
title: Supplementary Material for: Real World Postural Transitions as Biomarkers of Functional Impairment in Duchenne Muscular Dystrophy

description: Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder that impairs daily functioning and results in premature death. Current clinical assessments are widely used for characterizing functional impairment but have limitations due to their subjective and effort-based nature and because they only capture a snapshot of symptoms at a single point in time. Digital health technologies, such as wearable devices, allow continuous collection of movement and physiological data during daily life and could provide objective measures of the impact of DMD symptoms on daily functioning. For example, measurement of the 95th centile of stride velocity has recently gained endorsement by European regulators as an endpoint for evaluating functional changes in DMD, but the use of wearables for this purpose is just beginning. In this study, we present preliminary investigations of candidate digital biomarkers of functional impairment using real-world data, and further explore the relationships between these parameters and established clinical assessments. We found nine candidate biomarkers for detecting DMD-related functional impairment, all exhibiting large to very large effect sizes in our sample of 14 boys with DMD and matched controls (9 DMD, 5 control, age 4-12 years). Each candidate biomarker was moderately or strongly associated with clinical measures of function in DMD. Six of the biomarkers are novel and/or understudied in DMD including objective measures of gait acceleration and variability; postural control immediately before and after a postural transition; and the smoothness of postural transitions. Notably, postural transition measures were more sensitive to DMD-related impairment than gait, activity, and cardiac measures. These results suggest that the quality of postural transitions could serve as a sensitive and objective measure of functional impairment in DMD and point toward the need for further exploration of these measures in DMD.
DOI: 10.6084/m9.figshare.28722587
title: Supplementary Material for: Increasing prescription of SGLT2 inhibitors with expanded indications to the elderly population in Japan

description: Introduction: Indications for sodium-glucose cotransporter-2 (SGLT2) inhibitors have expanded to include heart failure and chronic kidney disease after the year 2020. Whether and how the demographic trends in the prescription of SGLT2 inhibitors have changed after indication expansion have not been studied extensively. 
Methods: This study is a descriptive analysis of serial, cross-sectional data on nationwide prescription of SGLT2 inhibitors between April 2016 and March 2023 obtained from NDB Open Data Japan, which contains more than 95% of total health insurance reimbursement claims in the nation. 
Results: The total number of SGLT2 inhibitor tablets prescribed in outpatient settings with prescription papers increased from 577,996,158 tablets in fiscal year (FY) 2020 to 904,598,175 tablets in FY 2022. Patients aged 75 years and older accounted for 20.3% of the total prescriptions in FY 2020, and this proportion increased to 27.8% in FY 2022. Among all SGLT2 inhibitors, the tablet that expanded its indications for patients with heart failure and chronic kidney disease the earliest showed the largest percentage increase in the number of prescribed tablets during this period and the highest share of the elderly population in its recipients in both sexes (men, 35.9%; women, 49.4%) in FY 2022. The number of prescribed SGLT2 inhibitor tablets per population was constantly higher in men than in women between FY 2020 and 2022, which is consistent with the sex difference in the prevalence of these diseases. 
Conclusion: Prescription of SGLT2 inhibitors to the elderly population is no longer infrequent and accounts for a large portion of the entire prescription of SGLT2 inhibitors in Japan. These findings contribute to updating our perception on the demographics of SGLT2 inhibitor recipients.
DOI: 10.6084/m9.figshare.28722587.v2
title: Supplementary Material for: Increasing prescription of SGLT2 inhibitors with expanded indications to the elderly population in Japan

description: Introduction: Indications for sodium-glucose cotransporter-2 (SGLT2) inhibitors have expanded to include heart failure and chronic kidney disease after the year 2020. Whether and how the demographic trends in the prescription of SGLT2 inhibitors have changed after indication expansion have not been studied extensively. 
Methods: This study is a descriptive analysis of serial, cross-sectional data on nationwide prescription of SGLT2 inhibitors between April 2016 and March 2023 obtained from NDB Open Data Japan, which contains more than 95% of total health insurance reimbursement claims in the nation. 
Results: The total number of SGLT2 inhibitor tablets prescribed in outpatient settings with prescription papers increased from 577,996,158 tablets in fiscal year (FY) 2020 to 904,598,175 tablets in FY 2022. Patients aged 75 years and older accounted for 20.3% of the total prescriptions in FY 2020, and this proportion increased to 27.8% in FY 2022. Among all SGLT2 inhibitors, the tablet that expanded its indications for patients with heart failure and chronic kidney disease the earliest showed the largest percentage increase in the number of prescribed tablets during this period and the highest share of the elderly population in its recipients in both sexes (men, 35.9%; women, 49.4%) in FY 2022. The number of prescribed SGLT2 inhibitor tablets per population was constantly higher in men than in women between FY 2020 and 2022, which is consistent with the sex difference in the prevalence of these diseases. 
Conclusion: Prescription of SGLT2 inhibitors to the elderly population is no longer infrequent and accounts for a large portion of the entire prescription of SGLT2 inhibitors in Japan. These findings contribute to updating our perception on the demographics of SGLT2 inhibitor recipients.
DOI: 10.6084/m9.figshare.28722587.v1
title: Supplementary Material for: Increasing prescription of SGLT2 inhibitors with expanded indications to the elderly population in Japan

description: Introduction: Indications for sodium-glucose cotransporter-2 (SGLT2) inhibitors have expanded to include heart failure and chronic kidney disease after the year 2020. Whether and how the demographic trends in the prescription of SGLT2 inhibitors have changed after indication expansion have not been studied extensively. 
Methods: This study is a descriptive analysis of serial, cross-sectional data on nationwide prescription of SGLT2 inhibitors between April 2016 and March 2023 obtained from NDB Open Data Japan, which contains more than 95% of total health insurance reimbursement claims in the nation. 
Results: The total number of SGLT2 inhibitor tablets prescribed in outpatient settings with prescription papers increased from 577,996,158 tablets in fiscal year (FY) 2020 to 904,598,175 tablets in FY 2022. Patients aged 75 years and older accounted for 20.3% of the total prescriptions in FY 2020, and this proportion increased to 27.8% in FY 2022. Among all SGLT2 inhibitors, the tablet that expanded its indications for patients with heart failure and chronic kidney disease the earliest showed the largest percentage increase in the number of prescribed tablets during this period and the highest share of the elderly population in its recipients in both sexes (men, 35.9%; women, 49.4%) in FY 2022. The number of prescribed SGLT2 inhibitor tablets per population was constantly higher in men than in women between FY 2020 and 2022, which is consistent with the sex difference in the prevalence of these diseases. 
Conclusion: Prescription of SGLT2 inhibitors to the elderly population is no longer infrequent and accounts for a large portion of the entire prescription of SGLT2 inhibitors in Japan. These findings contribute to updating our perception on the demographics of SGLT2 inhibitor recipients.
DOI: 10.6084/m9.figshare.28750598
title: Supplementary Material for: Clinical and Neurophysiological Effects of Robotically-Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Depression

description: Introduction:
Repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) is an established treatment for refractory major depressive disorder (MDD), but treatment outcomes vary substantially from person to person. Recent evidence suggests that incorporating neuroimaging-based targeting may help improve clinical outcomes. Here, we report the initial clinical outcomes of our open-label fMRI-personalized treatment protocol from the Queensland Neurostimulation Centre (QNC).
Methods:
This open-label, nonrandomized study was conducted between November 2021 and September 2024. Participants were a referred sample aged between 19 and 84, meeting the criteria for treatment-resistant MDD (N=61). They received 20 or 30-weekday sessions of DLPFC rTMS. The stimulation site was personalized using each individual’s fMRI brain connectivity data.
Results:
The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS). MADRS was lower post-treatment (d=1.78, p&lt;.001), with 52% and 33% response and remission rates observed. Likewise, anxiety scores (Hamilton Anxiety Rating Scale) were lower post-treatment (d=1.27, p&lt;.001), with 46% and 28% response and remission rates observed. The treatment was most effective in patients who qualified for randomized controlled trials (RCTs; N=19, MADRS response=74%, remission=53%) and least effective in patients with bipolar or neurological disorders (N=8, MADRS response=37%, remission=25%). Neurophysiologically, functional brain connectivity in the personalized DLPFC-SGC pathway was less anti-correlated post-treatment (d=0.63, p&lt;.001).
Conclusion:
Our findings provide new clinical and neurophysiological evidence supporting the high effectiveness of fMRI-connectivity-guided personalized rTMS for MDD, especially in individuals without complex comorbidities. The results encourage future RCTs to assess the superiority of personalized targeting over standard TMS.
DOI: 10.6084/m9.figshare.28750598.v1
title: Supplementary Material for: Clinical and Neurophysiological Effects of Robotically-Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Depression

description: Introduction:
Repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) is an established treatment for refractory major depressive disorder (MDD), but treatment outcomes vary substantially from person to person. Recent evidence suggests that incorporating neuroimaging-based targeting may help improve clinical outcomes. Here, we report the initial clinical outcomes of our open-label fMRI-personalized treatment protocol from the Queensland Neurostimulation Centre (QNC).
Methods:
This open-label, nonrandomized study was conducted between November 2021 and September 2024. Participants were a referred sample aged between 19 and 84, meeting the criteria for treatment-resistant MDD (N=61). They received 20 or 30-weekday sessions of DLPFC rTMS. The stimulation site was personalized using each individual’s fMRI brain connectivity data.
Results:
The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS). MADRS was lower post-treatment (d=1.78, p&lt;.001), with 52% and 33% response and remission rates observed. Likewise, anxiety scores (Hamilton Anxiety Rating Scale) were lower post-treatment (d=1.27, p&lt;.001), with 46% and 28% response and remission rates observed. The treatment was most effective in patients who qualified for randomized controlled trials (RCTs; N=19, MADRS response=74%, remission=53%) and least effective in patients with bipolar or neurological disorders (N=8, MADRS response=37%, remission=25%). Neurophysiologically, functional brain connectivity in the personalized DLPFC-SGC pathway was less anti-correlated post-treatment (d=0.63, p&lt;.001).
Conclusion:
Our findings provide new clinical and neurophysiological evidence supporting the high effectiveness of fMRI-connectivity-guided personalized rTMS for MDD, especially in individuals without complex comorbidities. The results encourage future RCTs to assess the superiority of personalized targeting over standard TMS.
DOI: 10.6084/m9.figshare.28750598.v2
title: Supplementary Material for: Clinical and Neurophysiological Effects of Robotically-Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Depression

description: Introduction:
Repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) is an established treatment for refractory major depressive disorder (MDD), but treatment outcomes vary substantially from person to person. Recent evidence suggests that incorporating neuroimaging-based targeting may help improve clinical outcomes. Here, we report the initial clinical outcomes of our open-label fMRI-personalized treatment protocol from the Queensland Neurostimulation Centre (QNC).
Methods:
This open-label, nonrandomized study was conducted between November 2021 and September 2024. Participants were a referred sample aged between 19 and 84, meeting the criteria for treatment-resistant MDD (N=61). They received 20 or 30-weekday sessions of DLPFC rTMS. The stimulation site was personalized using each individual’s fMRI brain connectivity data.
Results:
The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS). MADRS was lower post-treatment (d=1.78, p&lt;.001), with 52% and 33% response and remission rates observed. Likewise, anxiety scores (Hamilton Anxiety Rating Scale) were lower post-treatment (d=1.27, p&lt;.001), with 46% and 28% response and remission rates observed. The treatment was most effective in patients who qualified for randomized controlled trials (RCTs; N=19, MADRS response=74%, remission=53%) and least effective in patients with bipolar or neurological disorders (N=8, MADRS response=37%, remission=25%). Neurophysiologically, functional brain connectivity in the personalized DLPFC-SGC pathway was less anti-correlated post-treatment (d=0.63, p&lt;.001).
Conclusion:
Our findings provide new clinical and neurophysiological evidence supporting the high effectiveness of fMRI-connectivity-guided personalized rTMS for MDD, especially in individuals without complex comorbidities. The results encourage future RCTs to assess the superiority of personalized targeting over standard TMS.
DOI: 10.18739/a2513tz15
title: Nutrient availability, greenhouse gas fluxes, and environmental variables across burn treatments in the Yukon-Kuskokwim Delta, 2022-2023

description: The Yukon-Kuskokwim Delta (YKD) in southwestern Alaska in the discontinuous permafrost region is undergoing rapid change as a result of climate warming and disturbance. This area is made up upland peat plateau tundra interspersed with patchwork steams, fens, ponds, and lakes. In 2015, a tundra wildfire burned more than 541.54 square kilometers (km2) in the YKD, which is one of the larger tundra fires recorded in the area. This region has a wildfire history dating back to the last century. Researchers at the Woodwell Climate Research Center have been working in this region conducting terrestrial and aquatic studies to determine wildfire and permafrost thaw effects on carbon and nutrient cycling and vegetation change.
 These datasets were collected from the Izaviknek Uplands of the Yukon-Kuskokwim Delta during the growing seasons of 2022 and 2023. Ten 30-meter transects, each with 3 plots spaced out by 10-meters, were established across unburned tundra, the Izaviknek River fire scar (2015 wildfire), and Smitty fire scar (1972 wildfire), where co-located environmental variables (soil temperature, soil moisture, active layer depth), inorganic nitrogen availability (ammonium and nitrate), and greenhouse gas fluxes (carbon dioxide, methane, and nitrous oxide) were measured.
DOI: 10.15468/dl.mxnvnf
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"equals","key":"GADM_LEVEL_2_GID","value":"USA.11.12_1","matchCase":false},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0007548-260108223611665/datasets/export for details.
DOI: 10.15468/dl.rwkuyr
title: Occurrence Download

description: A dataset containing 1479 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Vampyressa thyone Thomas, 1909"
 ]
}

 The dataset includes 1479 records from 142 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011984-250415084134356/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.9pr7zf
title: Occurrence Download

description: A dataset containing 14772 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Dendroctonus W.F.Erichson, 1836"
 ]
}

 The dataset includes 14772 records from 162 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011983-250415084134356/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.t33wn4
title: Occurrence Download

description: A dataset containing 84 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Gonopterodendron carrapo (Killip & Dugand) Godoy-Bürki"
 ]
}

 The dataset includes 84 records from 25 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0010895-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rav246
title: Occurrence Download

description: A dataset containing 2236 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Quadrella indica (L.) Iltis & Cornejo",
 "BasisOfRecord is one of (Specimen, Fossil, Material sample, Material citation)"
 ]
}

 The dataset includes 2236 records from 117 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0010896-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.7u97a7
title: Occurrence Download

description: A dataset containing 758 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Amborellales"
 ]
}

 The dataset includes 758 records from 64 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0001971-250426092105405/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.f6uf2b
title: Occurrence Download

description: A dataset containing 1218 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Lampanyctus australis Tåning, 1932",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 1218 records from 31 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0001972-250426092105405/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/re1-s6b-pt5
title: Mammalia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/y24-vkv-e4d
title: Porites Link, 1807

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/2cp-t1h-2be
title: Mammalia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/vz0-mxy-6wb
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/1ah-ztz-g55
title: †Multescharipora d'Orbigny, 1853

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/fg1-j5w-92y
title: Hibolithes

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/h4w-vfr-l53
title: Muscardinus Kaup, 1829

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/jmn-f0e-0v0
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/daz-ef6-f0l
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/kp0-a41-l4r
title: Mammalia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/kq1-vy8-97e
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/rg9-34p-g6a
title: Apodemus sylvaticus (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.